LAUSR

1. Arrowsmith J. Trial watch: phase II failures: 2008-2010. Nat Rev Drug Discov 2011;10:328–329. 2. Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med 2014;20:195–203. 3. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315:801–810. 4. Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills TC, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med 2016;4:259–271. 5. Sweeney TE, Azad TD, Donato M, Haynes WA, Perumal TM, Henao R, et al. Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters. Crit Care Med 2018;46:915–925. 6. Scicluna BP, van Vught LA, Zwinderman AH, Wiewel MA, Davenport EE, Burnham KL, et al.; MARS Consortium. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med 2017;5:816–826. 7. Dunning JW, Merson L, Rohde GGU, Gao Z, Semple MG, Tran D, et al.; ISARIC Working Group 3, ISARIC Council. Open source clinical science for emerging infections. Lancet Infect Dis 2014;14:8–9. 8. Antcliffe DB, Burnham KL, Al-Beidh F, Santhakumaran S, Brett SJ, Hinds CJ, et al. Transcriptomic signatures in sepsis and a differential response to steroids: from the VANISH randomized trial. Am J Respir Crit Care Med 2019;199:980–986. 9. Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot J-P, Siami S, et al.; CRICS-TRIGGERSEP Network. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 2018;378: 809–818. 10. Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, et al.; ADRENAL Trial Investigators and the Australian–New Zealand Intensive Care Society Clinical Trials Group. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 2018;378: 797–808. 11. Famous KR, Delucchi K, Ware LB, Kangelaris KN, Liu KD, Thompson BT, et al.; ARDS Network. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med 2017;195:331–338. 12. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA. Latent class analysis of ARDS subphenotypes: analysis of data from two randomized controlled trials. Lancet Respir Med 2014;2: 611–620. 13. Russell CD, Baillie JK. Treatable traits and therapeutic targets: goals for systems biology in infectious disease. Curr Opin Syst Biol 2017;2: 139–145. 14. Baillie JK, Bretherick A, Haley CS, Clohisey S, Gray A, Neyton LPA, et al.; IIBDGC Consortium. Shared activity patterns arising at genetic susceptibility loci reveal underlying genomic and cellular architecture of human disease. PLoS Comput Biol 2018;14:e1005934. 15. Baillie JK. Translational genomics: targeting the host immune response to fight infection. Science 2014;344:807–808.